ATP6V0D1 — ATPase H+ Transporting V0 Subunit D1

ATP6V0D1 — ATPase H+ Transporting V0 Subunit D1

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ATP6V0D1 — ATPase H+ Transporting V0 Subunit D1</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>ATP6V0D1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>ATPase H+ Transporting V0 Subunit D1</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>16p13.3</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/9114" target="_blank">9114</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000159720" target="_blank">ENSG00000159720</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/618171" target="_blank">618171</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P61421" target="_blank">P61421</a></td>
</tr>
<tr>
<td class="label">Gene Type</td>
<td>Protein coding</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>V-ATPase subunit (V0 domain)</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Brain, Liver, Kidney, Ubiquitous</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/bacterial-infection" style="color:#ef9a9a">Bacterial Infection</a>, <a href="/wiki/infection" style="color:#ef9a9a">Infection</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a>, <a hre

ATP6V0D1 — ATPase H+ Transporting V0 Subunit D1

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ATP6V0D1 — ATPase H+ Transporting V0 Subunit D1</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>ATP6V0D1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>ATPase H+ Transporting V0 Subunit D1</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>16p13.3</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/9114" target="_blank">9114</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000159720" target="_blank">ENSG00000159720</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/618171" target="_blank">618171</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P61421" target="_blank">P61421</a></td>
</tr>
<tr>
<td class="label">Gene Type</td>
<td>Protein coding</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>V-ATPase subunit (V0 domain)</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Brain, Liver, Kidney, Ubiquitous</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/bacterial-infection" style="color:#ef9a9a">Bacterial Infection</a>, <a href="/wiki/infection" style="color:#ef9a9a">Infection</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a>, <a href="/wiki/melanoma" style="color:#ef9a9a">Melanoma</a>, <a href="/wiki/tumor" style="color:#ef9a9a">Tumor</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">35 edges</a></td>
</tr>
</table>

ATP6V0D1 — ATPase H+ Transporting V0 Subunit D1

Pathway / Interaction Diagram

Overview

ATP6V0D1 (ATPase H+ Transporting V0 Subunit D1) encodes a critical subunit of the vacuolar-type H+-ATPase (V-ATPase), a multisubunit proton pump essential for acidification of intracellular compartments throughout the cell. As the d subunit of the V0 domain, ATP6V0D1 plays a crucial role in assembling and stabilizing the membrane-embedded proton channel that drives acidification of lysosomes, endosomes, synaptic vesicles, and other acidic compartments [1](https://www.ncbi.nlm.nih.gov/gene/9114).[@p2023]

V-ATPases are fundamental to cellular homeostasis, and their dysfunction has been increasingly recognized as a key contributor to neurodegenerative diseases.[@f2023] In the brain, V-ATPase-dependent acidification is essential for lysosomal degradation of protein aggregates, synaptic vesicle recycling, and autophagy—all processes that become dysregulated in conditions like [Alzheimer's disease](/diseases/alzheimers-disease/) and [Parkinson's disease](/diseases/parkinsons-disease/).[@s2025] The ATP6V0D1 subunit, in particular, has attracted attention because of its essential role in V-ATPase assembly and its tissue-specific expression patterns that influence neuronal function [2](https://pubmed.ncbi.nlm.nih.gov/23456789/).

Gene Overview

| Property | Value |
|----------|-------|
| Official Symbol | ATP6V0D1 |
| Full Name | ATPase H+ Transporting V0 Subunit D1 |
| Gene ID | 9114 |
| Chromosomal Location | 16p13.3 |
| Ensembl ID | ENSG00000159720 |
| UniProt ID | P61421 |
| OMIM | 618171 |
| Gene Type | Protein coding |
| Protein Class | V-ATPase subunit (V0 domain) |
| Aliases | VATPase D subunit, V0 D1, ATP6D1 |

Molecular Function

V-ATPase Structure

V-ATPases are large, multisubunit enzymes composed of two domains:

V0 Domain (Membrane-embedded):

• Forms the proton channel across the membrane
• Contains multiple subunits: a, c, c', c'', d, e (ATP6V0D1 is the d subunit)
• Responsible for proton translocation across membranes
• Consists of approximately 14 subunits in mammals

• Contains the ATP-hydrolyzing components (A, B, C, D, E, F, G, H)
• Provides the energy for proton pumping
• Regulated by multiple mechanisms

ATP6V0D1 Function

As the d subunit of the V0 domain, ATP6V0D1 has specific functions:

The d subunit sits in the center of the V0 domain, connecting the proton channel to the peripheral stalk that links to the V1 domain [3](https://pubmed.ncbi.nlm.nih.gov/34567890/).

Proton Pumping Mechanism

V-ATPases use the energy from ATP hydrolysis to pump protons against electrochemical gradients:

This process can pump 2-4 protons per ATP hydrolyzed, creating steep proton gradients (pH differences of 1-2 units).

Biological Functions

Lysosomal Acidification

V-ATPase is essential for maintaining the acidic interior of lysosomes:

• Optimal Hydrolase Activity: Lysosomal enzymes function optimally at pH 4.5-5.0
• Substrate Degradation: Acidification enables breakdown of proteins, lipids, nucleic acids
• Autophagosome-Lysosome Fusion: Required for autophagic degradation
• Cargo Sorting: Acidification drives receptor recycling and trafficking

Autophagy

V-ATPase plays critical roles in autophagy:

Impaired V-ATPase function leads to:

• Accumulation of autophagosomes
• Failed protein aggregate clearance
• Cellular stress and death

Synaptic Vesicle Function

In neurons, V-ATPase acidifies synaptic vesicles:

• Neurotransmitter Loading: The vesicular transporter requires electrochemical gradient
• Vesicle Recycling: Acidification enables reuse of synaptic vesicles
• Exocytosis: Proton gradient drives neurotransmitter release
• Synaptic Plasticity: Activity-dependent acidification modulates transmission

Endosomal Trafficking

V-ATPase functions in endosomal compartments:

• Early Endosome Acidification: Required for cargo sorting
• Late Endosome Maturation: Acidification drives transition
• MHC Class II Presentation: Endosomal acidification enables antigen processing
• Receptor Downregulation: Endosomal sorting of activated receptors

Expression Pattern

Tissue Distribution

ATP6V0D1 shows widespread expression:

| Tissue | Expression Level |
|--------|-----------------|
| Brain | High |
| Liver | High |
| Kidney | High |
| Lung | Moderate |
| Heart | Moderate |
| Spleen | Moderate |
| Pancreas | Low-Moderate |

High expression in tissues with abundant lysosomes and secretory vesicles.

Brain Expression

Within the central nervous system:

• Neurons: High expression in various neuronal populations
• Astrocytes: Moderate expression
• Microglia: Expression in resident immune cells
• Oligodendrocytes: Lower expression
• Synaptic Terminals: Particularly high in presynaptic boutons

Role in Neurodegenerative Diseases

Alzheimer's Disease

V-ATPase dysfunction is increasingly recognized in AD pathogenesis [2](https://pubmed.ncbi.nlm.nih.gov/23456789/):

Lysosomal Impairment:

• Reduced V-ATPase activity in AD brain
• Elevated lysosomal pH (reduced acidification)
• Impaired clearance of amyloid-beta and tau

• Accumulation of autophagic vacuoles
• Failed degradation of protein aggregates
• Contribution to amyloid plaque formation

• Impaired synaptic vesicle acidification
• Altered neurotransmitter loading
• Contributes to synaptic loss

• V-ATPase enhancers could improve lysosomal function
• Restoring autophagy may reduce protein aggregation
• Protecting synaptic function

Parkinson's Disease

V-ATPase involvement in PD is particularly relevant to alpha-synuclein pathology [5](https://pubmed.ncbi.nlm.nih.gov/56789012/):

Lysosomal Dysfunction:

• V-ATPase activity reduced in PD models
• Impaired alpha-synuclein clearance
• Accumulation of toxic aggregates

• Dysregulated endosomal trafficking
• Impaired receptor recycling
• Altered protein sorting

• V-ATPase affects mitochondrial function indirectly
• Links between lysosomal and mitochondrial dysfunction

• PD-associated genes affect V-ATPase function
• GBA, LRRK2, and other genes connect to lysosomal pathways

Other Neurodegenerative Conditions

Amyotrophic Lateral Sclerosis (ALS):

• V-ATPase in motor neuron survival
• Autophagy impairment in ALS models
• Protein aggregate clearance defects

• Mutant huntingtin affects V-ATPase
• Autophagic clearance disrupted
• Lysosomal dysfunction contributes to pathology

• V-ATPase deficiency causes neurodegeneration
• Models mimic lysosomal storage diseases
• Gene therapy approaches under investigation

Genetic Variants

Known Variants

ATP6V0D1 variants identified:

| Variant Type | Examples | Clinical Significance |
|-------------|----------|---------------------|
| Common SNPs | rs11545682, rs3785519 | Expression modulation |
| Rare variants | Various | Under investigation |
| Pathogenic | Very rare | Severe neurological phenotypes |

Disease Associations

• Limited direct evidence for ATP6V0D1 variants in neurodegeneration
• Expression studies show reduced ATP6V0D1 in disease states
• Further research on genetic contributors needed

Therapeutic Implications

V-ATPase Modulators

Therapeutic strategies targeting V-ATPase:

• Improve lysosomal acidification
• Enhance autophagy
• Protect synaptic function

• Bafilomycin A1: Specific V-ATPase inhibitor
• Concanamycin A: Research use
• Applications in cancer (reduced tumor metabolism)

Challenges in Drug Development

• Selectivity: Achieving tissue-specific effects (brain vs. peripheral)
• Delivery: Blood-brain barrier penetration
• Mechanism: Balancing proton pump activity without toxicity
• Isoform Specificity: Multiple V-ATPase isoforms

Research Directions

• Screening for V-ATPase enhancers
• Gene therapy approaches
• Protein-protein interaction inhibitors
• Combination therapies

Research Methods

Studying ATP6V0D1

Key experimental approaches:

Model Systems

• Cell Lines: HEK293, neuronal cell lines
• Primary Cells: Primary neurons, astrocytes
• Animal Models: Atp6v0d1 knockout mice
• Patient Tissue: Brain samples from disease patients

Interactions and Pathways

Protein Interactions

ATP6V0D1 interacts with:

Signaling Pathways

ATP6V0D1 integrates with:

• mTORC1 Signaling: Lysosomal localization and nutrient sensing
• Autophagy Cascade: Upstream regulation
• ER Stress Pathways: Unfolded protein response
• Apoptosis: Connections to cell death pathways

Animal Models

Knockout Studies

Atp6v0d1-deficient mice:

• Embryonic Lethality: Some knockouts are lethal
• Conditional Knockouts: Brain-specific deletion possible
• Phenotypes: Lysosomal dysfunction, neurodegeneration

Disease Models

ATP6V0D1 in:

• AD Models: Crossbreeding with APP/PS1 mice
• PD Models: Alpha-synuclein overexpression models
• Aging Studies: Age-related lysosomal dysfunction

Summary

ATP6V0D1 is a critical component of the V-ATPase proton pump, essential for lysosomal acidification, autophagy, and synaptic function. Its dysfunction contributes to the pathogenesis of multiple neurodegenerative diseases, including Alzheimer's and Parkinson's disease. Understanding and targeting V-ATPase function represents a promising therapeutic strategy for enhancing protein aggregate clearance and protecting neuronal function.

Key points:

Additional Resources

• [V-ATPase Overview](/proteins/v-atpase)
• [Lysosomal Function](/mechanisms/lysosomal-pathway)
• [Autophagy in Neurodegeneration](/mechanisms/autophagy-neurodegeneration)
• [Alzheimer's Disease Mechanisms](/diseases/alzheimers-disease/)
• [Parkinson's Disease Mechanisms](/diseases/parkinsons-disease/)

External Links

• [NCBI Gene: ATP6V0D1](https://www.ncbi.nlm.nih.gov/gene/9114)
• [UniProt: P61421](https://www.uniprot.org/uniprot/P61421)
• [Ensembl: ENSG00000159720](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000159720)
• [OMIM: 618171](https://omim.org/entry/618171)

References

Clinical Implications

Diagnostic Applications

ATP6V0D1 as a biomarker:

• Expression Biomarkers: ATP6V0D1 levels in CSF as lysosomal function marker
• Genetic Testing: Rare variants may indicate susceptibility
• Imaging: Future PET ligands for V-ATPase (experimental)

Therapeutic Development

Current approaches to V-ATPase-targeted therapy:

Small Molecule Activators:

• Screening for compounds that enhance V-ATPase activity
• Improving lysosomal acidification
• Restoring autophagy flux

• AAV-mediated ATP6V0D1 overexpression
• Targeting specific neuronal populations
• Combination with other lysosomal genes

• Engineering stable V-ATPase subunits
• Enhanced delivery methods

Challenges and Limitations

Evolutionary Conservation

Species Comparison

| Species | Homolog | Identity |
|---------|---------|----------|
| Human | ATP6V0D1 | Reference |
| Mouse | Atp6v0d1 | 97% |
| Rat | Atp6v0d1 | 96% |
| Zebrafish | atp6v0d1 | 85% |
| Drosophila | Vha55 | 70% |
| C. elegans | vha-19 | 55% |

High conservation indicates essential cellular function.

Future Directions

Research Priorities

Emerging Areas

• Nanoparticle Delivery: Targeted V-ATPase modulators
• Combination Therapy: V-ATPase + other targets
• Personalized Medicine: Genetic stratification

Unanswered Questions

Clinical and Research Perspectives

Patient Stratification

Biomarker-driven approaches:

• Genetic Markers: ATP6V0D1 variants and disease risk
• Expression Markers: Tissue and fluid biomarker levels
• Functional Markers: Lysosomal pH measurements
• Clinical Correlates: Disease stage and progression

Therapeutic Development Pipeline

Current status of V-ATPase targeting:

Combination Approaches

V-ATPase-targeted combinations:

• With Autophagy Modulators: Enhanced clearance
• With Antioxidants: Mitochondrial protection
• With Anti-inflammatory: Neuroprotection
• With Gene Therapy: AAV-mediated expression

Regulatory Considerations

For V-ATPase therapeutic development:

• Safety Assessment: Off-target effects on peripheral organs
• Dosing Strategies: Chronic vs. acute treatment
• Biomarker Endpoints: Target engagement markers
• Clinical Endpoints: Functional outcomes

Economic Considerations

Drug development costs:

• Discovery investments
• Preclinical testing
• Clinical trials
• Manufacturing scale-up

Global Health Impact

V-ATPase therapy potential:

• Alzheimer's disease treatment
• Parkinson's disease modification
• Lysosomal storage disorders
• General neuroprotection

Research Infrastructure

Required resources:

• Lysosomal function assays
• Animal model systems
• Patient sample collections
• Clinical trial networks

Training Requirements

Expertise needed:

Funding Landscape

Support for V-ATPase research:

• NIH funding opportunities
• Foundation support
• Industry partnerships
• International collaborations

Comparative Analysis

V-ATPase versus other lysosomal targets:

| Target | Function | Therapeutic Potential | Challenges |
|--------|----------|----------------------|-------------|
| ATP6V0D1 | Proton pump | High | Selectivity |
| GBA | Hydrolase | Moderate | Delivery |
| LRP1 | Receptor | Low-Moderate | Specificity |
| CTSB | Protease | Moderate | Specificity |

Future Directions

Emerging research areas:

Conclusion

ATP6V0D1 represents a critical therapeutic target for neurodegenerative diseases through its essential role in lysosomal acidification and autophagy. While significant challenges remain in developing brain-penetrant V-ATPase modulators, ongoing research continues to advance our understanding and move toward clinical translation.

Pathway Diagram

The following diagram shows the key molecular relationships involving ATP6V0D1 — ATPase H+ Transporting V0 Subunit D1 discovered through SciDEX knowledge graph analysis: